Korea Investment Partners is leading the Series B Plus financing and existing investors will also join the round, reports Pharmtech Focus.

Eyevensys, a developer of therapies for ophthalmic diseases raised $12 million in Series B+ funding.

A non-viral gene therapy sustained drug-delivery product that delivers anti-VEGF to the eye may replace the need for repeated intravitreal anti-VEGF injections and improve vision in patients with wet AMD.

LABIOTECH.eu reports on Eyevensys and other innovative companies developing gene therapy treatments with the potential to cure different forms of genetic blindness.

Eyevensys CEO, Patricia Zilliox, discusses innovation as a key component of growth in the medical and pharmaceutical industry, what her work has taught her about fundraising, and the impact of the pandemic on her work.

Watch Eyevensys Founder and Chief Innovation Officer, Prof. Francine Behar-Cohen, present at the OIS Ocular Drug Delivery Meeting, providing details about our innovative non-viral gene therapies for the treatment of ocular diseases and our active pipeline and strategy.

Eyevensys founder, Francine Behar-Cohen, and Scientific Director, Thierry Bordet talk to Le Figaro about the company’s innovative treatments and technology in development for treating eye diseases. (article and video)

Listen to Patricia Zilliox, CEO of Eyevensys, discuss her background, her industry experience and expertise, and her passion for developing treatments to improve patient outcomes.

Patricia Zilliox, CEO of Eyevensys, discusses building the company’s presence in the US.

Patricia Zilliox, CEO of Eyevensys speaks about raising €27M to fund the launch of a phase II trial for its lead candidate, a non-viral gene therapy for an eye condition called uveitis that can lead to blindness.